Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.51 |
| ▸ | ITGAV | P06756 | 6/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15592461 | 1.00 | ITGB3 (0.51) | ITGB3ITGAVKCNA5ITGA2BTBXAS1 | |
| SCHEMBL1209573 | 0.83 | L3MBTL1 (0.56) | ITGB3ITGAVKCNA5ITGA2BTBXAS1 | |
| SCHEMBL15267199 | 0.83 | KCNA5 (0.69) | KCNA5 | |
| SCHEMBL1234229 | 0.81 | TAAR1 (0.55) | — | |
| SCHEMBL25152144 | 0.81 | TAAR1 (0.55) | — | |
| SCHEMBL25152385 | 0.81 | TAAR1 (0.55) | — | |
| SCHEMBL5856512 | 0.80 | TBXAS1 (0.53) | ITGB3ITGAVITGA2BTBXAS1CTSA | |
| SCHEMBL20784917 | 0.80 | SMN1; SMN2 (0.47) | KCNA5L3MBTL1SMN1; SMN2CFTRSLC6A2 | |
| SCHEMBL25152516 | 0.79 | ITGB3 (0.47) | ITGB3ITGAVITGA2BTBXAS1L3MBTL1 | |
| SCHEMBL25152962 | 0.79 | ITGB3 (0.47) | ITGB3ITGAVITGA2BTBXAS1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | ITGB3 1004/4885ITGAV 1053/4885KCNA5 688/4885 |
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | ITGB3 1004/4885ITGAV 1053/4885KCNA5 688/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | ITGB3 1004/4885ITGAV 1053/4885KCNA5 688/4885 |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | ITGB3 1004/4885ITGAV 1053/4885KCNA5 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.